Compare Adaptive Biotechnologies Corp (ADPT) vs Prudential Financial Inc (PRU) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Prudential Financial Inc — how do they compare? Adaptive Biotechnologies Corp trades at $19.94 (market cap $3.33B), while Prudential Financial Inc trades at $112.92 (market cap $40.11B). The key difference: Prudential Financial Inc is far larger — about 12× Adaptive Biotechnologies Corp's market cap, and Prudential Financial Inc pays a 4.85% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | PRU | |
|---|---|---|
Market Cap | $3.33B | $40.11B |
Sector | Health | Financials |
52-Week High | $22.37 | $118.72 |
52-Week Low | $10.24 | $92.00 |
Enterprise Value | $3.19B | $67.16B |
Dividend Yield | — | 4.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
PRU trades at $115.47, up 2.23% today, with a bullish technical signal and strong moving average support. The company reported a net income margin of 5.5% in 2025, with recent earnings beats in Q1 2026. Recent developments include expansion in India's life insurance market and new ETF launches by PGIM, highlighting growth initiatives.
Outlook remains positive due to solid profitability and strategic expansions, but risks include volatile cash flows and high debt levels. Analyst consensus is cautious with a hold-heavy rating, though the current price exceeds the $98.64 target, suggesting limited near-term upside amid steady operational performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Prudential Financial Inc
Prudential Financial is a large, diversified insurance company offering annuities, life insurance, retirement plan services, and asset management products. While it operates in a number of countries, the vast majority of revenue is generated in the United States and Japan. The company's investment management business, PGIM, contributes approximately 15% of its earnings and has over $1.5 trillion in assets under management. The U.S. businesses are responsible for about 45% of earnings and can be classified into Institutional Retirement Strategies, Individual Retirement Strategies, Group Insurance, Individual Life Insurance, and Assurance IQ. Finally, the international business segment of the company contributes approximately 40% of earnings with a strong market position in Japan.
Read more on PRU →
